Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
SNY
STRONG BUYSanofi · Healthcare · France · $102.8B · Avg Vol: $163M/d
COMPANY DESCRIPTION
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare solutions, encompassing prescription drugs, vaccines, and consumer healthcare products. Its significant competitive moat stems from a highly diversified portfolio of patented drugs and vaccines, strong global R&D capabilities, and extensive commercial reach across multiple therapeutic areas. Sanofi is a leading multinational pharmaceutical firm, particularly prominent in vaccine production and innovation in rare diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.2B | 47.4B | 50.4B | 53.2B | 4.8% | 53.9B | 57.6B | 61.3B | 7.3% |
| EPS | 3.06 | 2.45 | 2.61 | 3.64 | 6.0% | 2.31 | 3.74 | 4.01 | 4.9% |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | — | — | — | — |
| Debt | 24.2B | 21.0B | 20.4B | 23.2B | -1.4% | 22.8B | — | — | — |
| Equity | 85.2B | 84.3B | 88.3B | 81.3B | -1.5% | — | — | — | — |
| Op CF | 12.0B | 11.7B | 10.3B | 12.2B | 0.7% | 11.8B | — | — | — |
| Inv CF | -2.4B | -7.1B | -5.0B | -2.8B | — | — | — | — | — |
| Fin CF | -6.6B | -9.2B | -6.6B | -9.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNY | Sanofi(you) | $102.8B | 96 | STRONG BUY |
| GSK | GSK plc | $105.2B | 95 | STRONG BUY |
| BMY | Bristol-Myers Squibb Company | $117.5B | 99 | STRONG BUY |
| PFE.MX | Pfizer Inc. | $137.8B | 95 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $158.8B | 95 | STRONG BUY |
| AMGN.MX | Amgen Inc. | $192.8B | 96 | STRONG BUY |
| BAYN.DE | Bayer Aktiengesellschaft | $52.6B | 91 | STRONG BUY |
| NVON.MX | Novo Nordisk A/S | $212.5B | 90 | STRONG BUY |
| ROP.SW | Roche Holding AG | $323.7B | 97 | STRONG BUY |
| MRK.MX | Merck & Co., Inc. | $316.3B | 98 | STRONG BUY |
Peer medians: ROE 2.7% · P/E 22.9x · Gross margin 47.5%